Companies & Sponsors

argenx is an immunology company built on FcRn biology, with efgartigimod (VYVGART) approved in myasthenia gravis and under study across additional IgG-mediated autoimmune diseases.

AstraZeneca is a global biopharmaceutical company with a deep oncology franchise, including the anti-PD-L1 antibody durvalumab (IMFINZI) and the DNA-damage-response inhibitor ceralasertib.

Belite Bio is a clinical-stage biopharmaceutical company developing oral therapies for degenerative retinal diseases, led by the RBP4 antagonist tinlarebant for Stargardt disease and geographic atrophy.

Capricor Therapeutics is a biotechnology company developing cell and exosome therapies, with its lead cardiosphere-derived cell product deramiocel (CAP-1002) focused on the skeletal and cardiac manifestations of Duchenne muscular dystrophy.

DBV Technologies is a clinical-stage company pioneering epicutaneous (skin-patch) immunotherapy, with its VIASKIN platform aimed at desensitizing children with food allergies such as peanut allergy.

Dyne Therapeutics develops muscle-targeted oligonucleotide therapies using its FORCE platform, advancing exon-skipping candidates for Duchenne muscular dystrophy and myotonic dystrophy.

Eli Lilly is a global pharmaceutical company and a leader in cardiometabolic medicine, developing the oral GLP-1 receptor agonist orforglipron alongside its incretin franchise for obesity and type-2 diabetes.

Foresee Pharmaceuticals is a clinical-stage company built around long-acting injectable formulations, including six-month leuprolide depots for hormone-driven conditions such as central precocious puberty and prostate cancer.

Galapagos is a biotechnology company with a heritage in immunology and kinase biology, advancing the selective TYK2 inhibitor GLPG3667 across autoimmune diseases including dermatomyositis and systemic lupus erythematosus.

Hansa Biopharma develops IgG-cleaving enzyme therapeutics based on the IdeS technology, with imlifidase used to rapidly remove pathogenic antibodies in transplantation and acute autoimmune disease.

Immunome is an oncology-focused biotechnology company whose pipeline includes the gamma-secretase inhibitor varegacestat (formerly AL102) for desmoid tumors.

Insmed is a biopharmaceutical company focused on serious and rare respiratory diseases, advancing the oral DPP1 inhibitor brensocatib across neutrophil-driven conditions such as bronchiectasis and chronic rhinosinusitis.

Johnson & Johnson is a diversified global healthcare company whose innovative-medicine pipeline spans immunology and dermatology, including investigational programs in atopic dermatitis.

Kamada is a plasma-derived and specialty biopharmaceutical company, developing inhaled alpha-1 antitrypsin for the lung manifestations of alpha-1 antitrypsin deficiency.

Nektar Therapeutics is a biopharmaceutical company developing immunomodulatory therapeutics, including the regulatory-T-cell-stimulating IL-2 conjugate rezpegaldesleukin for inflammatory and autoimmune diseases.

Structure Therapeutics is a clinical-stage company designing oral small-molecule medicines for chronic diseases, led by the oral GLP-1 receptor agonist aleniglipron (GSBR-1290) for obesity.